Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5

Haematologica

Volumn 97, Issue 12, 2012, Pages 1855-1863

  Pegon, Julie N ^a   Kurdi, Mohamad ^a   Casari, Caterina ^a   Odouard, Soline ^a   Denis, Cécile V ^a,b   Christophe, Olivier D ^a,b   Lenting, Peter J ^a,b  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Factor VIII; Interaction; Ligand; Siglec 5; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; LECTIN; PROTEIN SIGLEC 7; SIALIDASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOADSORBENT; IMMUNOHISTOCHEMISTRY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELLS, CULTURED; ENDOCYTOSIS; ENDOSOMES; FACTOR VIII; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; LECTINS; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES; POLYSACCHARIDES; VON WILLEBRAND FACTOR;

EID: 84870437422     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.063297     Document Type: Article

References (26)

1. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998;92 (11):3983-96.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67:395-424.
3. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor-- too sweet for their own good. Haemophilia 2010;16 (Suppl 5):194-9.
4. Hironaka T, Furukawa K, Esmon PC, Fournel MA, Sawada S, Kato M, et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992;267(12):8012-20.
5. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992;267(13):8723-31.
6. Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, Laffan M, et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost 2010;8(1):137-45.
7. Schilow WF, Schoerner-Burkhardt E, Seitz R. Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards. Thromb Haemost 2004;92(2):427-8.
8. Lock K, Zhang J, Lu J, Lee SH, Crocker PR. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte- derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 2004; 209(1-2):199-207.
9. Jandus C, Simon HU, von Gunten S. Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol 2011;82(4):323-32.
10. Cornish AL, Freeman S, Forbes G, Ni J, Zhang M, Cepeda M, et al. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood 1998;92(6):2123-32.
11. Zhuravleva MA, Trandem K, Sun PD. Structural implications of Siglec-5-mediated sialoglycan recognition. J Mol Biol 2008;375 (2):437-47.
12. Brinkman-Van der Linden EC, Varki A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J Biol Chem 2000;275(12):8625-32.
13. Carlin AF, Chang YC, Areschoug T, Lindahl G, Hurtado-Ziola N, King CC, et al. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med 2009;206(8): 1691-9.
14. Erickson-Miller CL, Freeman SD, Hopson CB, D'Alessio KJ, Fischer EI, Kikly KK, et al. Characterization of Siglec-5 (CD170) expression and functional activity of anti- Siglec-5 antibodies on human phagocytes. Exp Hematol 2003;31(5):382-8.
15. Avril T, Freeman SD, Attrill H, Clarke RG, Crocker PR. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J Biol Chem. 2005; 280(20):19843-51.
16. Jones C, Virji M, Crocker PR. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol Microbiol 2003;49(5):1213-25.
17. Rapoport EM, Sapot'ko YB, Pazynina GV, Bojenko VK, Bovin NV. Sialoside-binding macrophage lectins in phagocytosis of apoptotic bodies. Biochemistry (Mosc.) 2005;70 (3):330-8.
18. van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, van den Berg HM, Denis CV, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008;112(5):1704-12.
19. Casale TB, Kaliner M. A rapid method for isolation of human mononuclear cells free of significant platelet contamination. J Immunol Methods 1982;55(3):347-53.
20. Lenting PJ, Christophe OD, Gueguen P. The disappearing act of factor VIII. Haemophilia 2010;16(102):6-15.
21. Dam TK, Brewer CF. Effects of clustered epitopes in multivalent ligand-receptor interactions. Biochemistry 2008;47(33): 8470-6.
22. Varki A. Natural ligands for CD33-related Siglecs? Glycobiology. 2009;19(8):810-2.
23. Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274(34):23734-9.
24. Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptorrelated protein deficiency. Blood 2003;101 (10):3933-9.
25. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009;15(6):1187-96.
26. Lenting PJ, Van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-60.